Category: Whitepapers

Archive

Categories

Category Tags

409A valuation AI Medical Service AOT asset valuation Biotech firms Biotechgate Biotechgate Digital Partnering brain activity measuring breast cancer Cells clinical trial database Cold Ablation Robotguided Laser Osteotome cranio-maxillofacial surgery Cyrill Bätscher early digestive track cancer detection Ferring Pharmaceutical filming Fujieda Ayumi Funding future of life sciences Gergely Ivanyi German Biotech German Life Sciences GTAI Health Made in Germany Heartseed Inc. HelloPartnering in-licensing opportunities JPM San Francisco Kiyoshi Hasegawa life science database Lily MedTech Inc. medical image analysis NeU Corporation patrik frei product valuation RESI Rhine-Main-Neckar biotech SARS CoV 2 Shiho Azuma Tomohiro Tada valuation Valuation Experts XB-01 Yone Production Co Ltd

Socials Share

  • Whitepaper: Life Sciences – 409A valuation vs. valuation to raise money

    Venture Valuation

    The US Internal Revenue Code has numerous regulations which must be adhered to in order for companies to reach compliance standards. One such regulation, Section 409A of the IRC, governs the complexities of setting strike prices for employee stock options and requires that companies be properly audited before issuing stock options as employee compensation.

    Often there is some confusion as to what the difference is between a so-called 409A valuation as required by the IRS, and a valuation to raise money. Venture Valuation compiled a white paper to provide a short overview of the key differences.

    Download the whitepaper

    Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?

  • Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals

    Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals

    Venture Valuation

    Switzerland, March 2019: Venture Valuation has been working with Ferring Pharmaceutical supporting the company with external, third-party product/asset valuations of potential in-licensing opportunities. After Ferring had identified a specific opportunity and deemed interesting to move it forward in the internal evaluation process, Venture Valuation was mandated to review the product/opportunity from an external point of view. Ferring are looking for collaborations within women’s health, specifically treatments regarding fertility, reproductive cycle, pregnancy, and childbirth.

    Download the whitepaper

    Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?

  • Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech

    Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech

    Venture Valuation

    Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector.  Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years.

    Analysing this data from the Biotechgate database, which tracks financial rounds in the Biotech sector revels two key trends: 1) Larger investment deals and 2) A larger proportion of Series A and Series B deals.

    So, what factors have been driving larger, earlier investment in biotech firms?

    Download the whitepaper

    Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?

  • Whitepaper: Focus on the Antibiotics Market

    Whitepaper: Focus on the Antibiotics Market

    Venture Valuation

    The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases is contributing to the market growth, especially in developing regions such as Asia-Pacific. However, raising capital for companies active in this field has been difficult for the past few years. Thus, Venture Valuation has collected some important facts, figures, and background information about antibiotics financing, including key investors, the biggest financing rounds, and financing trends.

    Download the whitepaper.